| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 0 | 41 | 6.833 | 10.534 | 16.790 | 14.907 |
| Total Income - EUR | - | - | - | - | 0 | 531 | 12.575 | 16.294 | 22.532 | 20.141 |
| Total Expenses - EUR | - | - | - | - | 239 | 2.779 | 14.120 | 14.986 | 16.071 | 16.279 |
| Gross Profit/Loss - EUR | - | - | - | - | -239 | -2.248 | -1.545 | 1.309 | 6.461 | 3.863 |
| Net Profit/Loss - EUR | - | - | - | - | -239 | -2.249 | -1.750 | 993 | 5.427 | 3.245 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Nefromedica S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 5.034 | 24.471 | 17.893 | 11.895 | 5.823 | 288 |
| Current Assets | - | - | - | - | 8 | 33 | 165 | 1.003 | 2.692 | 3.904 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | - | - | - | - | 8 | 33 | 165 | 1.003 | 2.692 | 3.904 |
| Shareholders Funds | - | - | - | - | -197 | -2.442 | -4.138 | -3.158 | 2.279 | 3.293 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 212 | 3.946 | 5.448 | 5.016 | 971 | 899 |
| Income in Advance | - | - | - | - | 5.028 | 23.001 | 16.749 | 11.040 | 5.264 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Nefromedica S.r.l.